Connecting oncology, clinical evidence and healthcare innovation
Victoria brings clinical research and drug development experience to discussions about how oncology teams choose their next question. At a pancreatic cancer conference, she introduced and moderated a session about Precision Promise, an adaptive clinical trial platform. That example gives planners a concrete starting point for a discussion about trial design and evidence.
This session examines the clinical and organizational considerations involved in advancing cancer research. It focuses on the relationship between a research question, meaningful evidence and the decisions that follow.
Audience takeaways
Identify the clinical question a research program must address.
Distinguish evidence needs at different decision points.
Recognize organizational considerations that affect progress.
Clinical development and commercialization involve connected but different decisions. This session explores how leaders assess evidence, development priorities and the path toward bringing a product into use.
Audience takeaways
Separate clinical development milestones from commercial decisions.
Identify evidence needed at an important transition point.
Frame questions that connect development choices with intended use.
Clinical insight can help shape the assessment of healthcare innovation. This session examines how leaders consider a company’s underlying need, evidence and development path when discussing investment and growth.
Audience takeaways
Define the clinical need behind a healthcare company’s proposition.
Identify evidence gaps that matter to an assessment.
Connect development plans with questions about implementation and growth.
Oncology, clinical research, drug development and healthcare investment
Victoria Manax Rutson, MD, is a medical oncologist, biotechnology executive and General Partner at Eckuity Capital. Her background spans clinical development, commercialization and healthcare investment.
She previously held executive roles at Celgene and served as the inaugural Chief Medical Officer of the Pancreatic Cancer Action Network. She brings clinical and industry perspectives to discussions about oncology research, evidence generation and bringing healthcare innovations into practice.